Milestone Scientific Receives CE Mark Approval of Pain-Free Single Tooth Anesthesia (STA(TM)) System
June 20 2007 - 9:30AM
PR Newswire (US)
LIVINGSTON, N.J., June 20 /PRNewswire-FirstCall/ -- Milestone
Scientific, Inc. (OTC:MLSS) (BULLETIN BOARD: MLSS) , the recognized
leader in advanced injection technologies, today announced that it
has been granted CE Mark approval for its award winning Single
Tooth Anesthesia (STA(TM)) System. This approval permits the
Company to begin marketing the STA System to dental professionals
in European Union countries and other countries around the world
that recognize the CE Mark approval process. "We are very pleased
to receive CE Mark approval for the STA System, which represents
yet another key step forward in the execution of our global
marketing and commercialization strategy for this novel product,"
stated Leonard Osser, Chairman and CEO of Milestone Scientific.
"Considering key countries within the European Union will boast a
near $33 billion collective market for professional dentistry
services in 2008, according to the recent Barnes Report, this
presents a compelling growth opportunity for Milestone and gives us
more than ample customer targets to pursue as we advance STA's
worldwide market penetration initiatives." The FDA-cleared STA
System, recently distinguished as a "2007 Top 100 Product" by
leading industry publication Dentistry Today, is comprised of a
computer-controlled drive unit and a single-use disposable
handpiece/needle assembly. It provides newly-patented, real-time
visual and audible feedback and verbal announcements via
Milestone's patented CompuFlo(TM) with Dynamic Pressure Sensing
(DPS(TM)) technology, thus taking the guesswork out of the
administration of anesthetic. Specifically, the STA System enables
the dental professional to precisely administer an intraligamentary
injection to anesthetize a single tooth in only one or two minutes,
rather than administering a mandibular block that anesthetizes an
entire quadrant. The STA intraligamentary injection has an
immediate onset, whereas the typical block injection can take eight
to 12 minutes before a dentist can start treatment. The dental
literature shows that approximately 30 percent of mandibular block
injections are missed due to limitations of technique and delivery.
This can add another five to ten minutes to the time a patient has
to wait to be reinjected by the dentist. In addition, the STA
intraligementary injection lasts as long as a traditional
infiltration or mandibular block. All of this is accomplished with
a technology that has been clinically proven to provide a pain-free
injection. For more information, contact Milestone Scientific at
(877) STA-IS4U or visit http://www.stais4u.com/. About Milestone
Scientific, Inc. Headquartered in Livingston, New Jersey, Milestone
Scientific is engaged in pioneering proprietary, highly innovative
technological solutions for the medical and dental markets. Central
to the Company's IP platform and product development strategy is
its patented CompuFlo(TM) technology for the improved and painless
delivery of local anesthetic. Specifically, CompuFlo is a
computer-controlled, pressure sensitive infusion, perfusion,
suffusion and aspiration technology, which provides real-time
readouts of pressures, fluid densities and flow rates, enabling the
advanced delivery and removal of a wide array of fluids. The Single
Tooth Anesthesia (STA(TM)) computer-controlled local anesthesia
delivery system which uses this technology provides dentists with
audible and visual signals as to in-tissue pressure. Milestone's
existing painless injection systems are currently sold in 25
countries. For more information on these and other innovative
Milestone products, please visit the Company's web site found at
http://www.milesci.com/. Safe Harbor Statement This press release
contains forward-looking statements regarding the timing and
financial impact of the Milestone's ability to implement its
business plan, expected revenues and future success. These
statements involve a number of risks and uncertainties and are
based on assumptions involving judgments with respect to future
economic, competitive and market conditions and future business
decisions, all of which are difficult or impossible to predict
accurately and many of which are beyond Milestone's control. Some
of the important factors that could cause actual results to differ
materially from those indicated by the forward-looking statements
are general economic conditions, failure to achieve expected
revenue growth, changes in our operating expenses, adverse patent
rulings, FDA or legal developments, competitive pressures, changes
in customer and market requirements and standards, and the risk
factors detailed from time to time in Milestone's periodic filings
with the Securities and Exchange Commission, including without
limitation, Milestone's Annual Report on Form 10-KSB for the year
ended December 31, 2006. The forward looking-statements in this
press release are based upon management's reasonable belief as of
the date hereof. Milestone undertakes no obligation to revise or
update publicly any forward-looking statements for any reason. FOR
MORE INFORMATION, PLEASE CONTACT: Elite Financial Communications
Group, LLC Dodi Handy, President and CEO, or Daniel Conway, Chief
Strategist 407-585-1080 or via email at DATASOURCE: Milestone
Scientific, Inc. CONTACT: Dodi Handy, President and CEO, or Daniel
Conway, Chief Strategist, both +1-407-585-1080, , of Elite
Financial Communications Group, LLC, for Milestone Scientific, Inc.
Web site: http://www.milesci.com/ http://www.stais4u.com/
Copyright